AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Immucell Corp
XNAS · usd
SIC 2835 · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
FIGI BBG001S5S3P1
10.25▼ 0.19 (-1.82%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
10.44
Day's Range
10.19 – 10.37
52-Week Range
4.52 – 12.10
Volume
11.3K
Avg Volume
12.0K
Share Statistics
Shares Outstanding
Employees
73
Exchange
XNAS
Listed
1987-07-08
Share count as of July 31, 2026

Immucell Corp (ICCC) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Immucell Corp (ICCC)
What is Immucell Corp's Market Cap?
Immucell Corp's Market Cap is $93.1M, based on as-reported figures from SEC (XBRL) filings.
What is Immucell Corp's Enterprise Value?
Immucell Corp's Enterprise Value is $92.5M, based on as-reported figures from SEC (XBRL) filings.
What is Immucell Corp's Trailing P/E?
Immucell Corp's Trailing P/E is 118.2×, based on as-reported figures from SEC (XBRL) filings.
What is Immucell Corp's Price / Sales?
Immucell Corp's Price / Sales is 3.0×, based on as-reported figures from SEC (XBRL) filings.
What is Immucell Corp's EV / Revenue?
Immucell Corp's EV / Revenue is 3.0×, based on as-reported figures from SEC (XBRL) filings.
What is Immucell Corp's EV / EBITDA?
Immucell Corp's EV / EBITDA is 14.7×, based on as-reported figures from SEC (XBRL) filings.
What is Immucell Corp's Revenue (TTM)?
Immucell Corp's Revenue (TTM) is $30.7M, based on as-reported figures from SEC (XBRL) filings.
What is Immucell Corp's Net Income (TTM)?
Immucell Corp's Net Income (TTM) is $787.4K, based on as-reported figures from SEC (XBRL) filings.
What is Immucell Corp's EBITDA?
Immucell Corp's EBITDA is $6.3M, based on as-reported figures from SEC (XBRL) filings.
What is Immucell Corp's Diluted EPS (TTM)?
Immucell Corp's Diluted EPS (TTM) is 0.09, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · ICCCAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Product sales
YoY growth+11.5%+28.4%-1.6%-8.4%
Costs of goods sold
Gross profit
% of revenue33.9%45.0%38.2%42.9%
Administrative expenses
Sales and marketing expenses
Product development expenses
Other operating income———
Operating expenses (income)
% of revenue7.0%26.0%38.9%42.6%
NET OPERATING INCOME (LOSS)
% of revenue26.9%19.0%-0.8%0.4%
Other (expenses) income, net
INCOME BEFORE INCOME TAXES
Income tax expense
NET INCOME
% of revenue25.5%18.7%-37.4%-2.5%
Basic net income per share (in dollars per share)
Diluted net income per share (in dollars per share)